精神分裂症药物评估。基础试验设计。
Assessment of drugs in schizophrenia. Basic trial design.
作者信息
Lader M
出版信息
Br J Clin Pharmacol. 1976 Jun;3(3 Suppl 2):375-9. doi: 10.1111/j.1365-2125.1976.tb03728.x.
Abstract
Clinical trials with major tranquilizers must take into account the clinical features of patients with schizophrenia and pharmacokinetic and pharmacodynamic properties of the drug. The objectives of the trial must be carefully defined so that appropriate selection criteria for patients, rating instruments and dosage schedules can be selected. It is useful to monitor physiological and biochemical actions of major tranquilizers as well as the clinical effects.
摘要
使用主要镇静剂的临床试验必须考虑精神分裂症患者的临床特征以及药物的药代动力学和药效学特性。必须仔细界定试验目标，以便能够选择合适的患者入选标准、评定工具和给药方案。监测主要镇静剂的生理和生化作用以及临床效果很有必要。
相似文献
1
Assessment of drugs in schizophrenia. Basic trial design.精神分裂症药物评估。基础试验设计。
Br J Clin Pharmacol. 1976 Jun;3(3 Suppl 2):375-9. doi: 10.1111/j.1365-2125.1976.tb03728.x.
2
Dose selection and comparator drugs in schizophrenia research.精神分裂症研究中的剂量选择与对照药物
J Clin Psychiatry. 2001;62 Suppl 9:29-32; discussion 33-4.
3
Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.精神分裂症随机非典型抗精神病药物试验中的对照组偏倚。
Arch Gen Psychiatry. 2005 Sep;62(9):961-70. doi: 10.1001/archpsyc.62.9.961.
4
The CATIE study.CATIE研究。
Am J Psychiatry. 2006 Mar;163(3):554-5; author reply 555-6. doi: 10.1176/appi.ajp.163.3.554.
5
Patient-oriented randomisation: A new trial design applied in the Neuroleptic Strategy Study.以患者为导向的随机分组：一种应用于抗精神病药物策略研究的新试验设计。
Clin Trials. 2016 Jun;13(3):251-9. doi: 10.1177/1740774516639910. Epub 2016 Mar 25.
6
Schizophrenia and antipsychotic somatic treatment.
Int J Technol Assess Health Care. 1996 Fall;12(4):573-84. doi: 10.1017/s0266462300010898.
7
Emerging guidelines for the use of antipsychotic polypharmacy.抗精神病药物联合使用的新兴指南。
Rev Psiquiatr Salud Ment. 2013 Jul-Sep;6(3):97-100. doi: 10.1016/j.rpsm.2013.01.001. Epub 2013 Feb 26.
8
Assessment of drugs in schizophrenia. Discussion on basic trial design.精神分裂症药物评估。关于基本试验设计的讨论。
Br J Clin Pharmacol. 1976 Jun;3(3 Suppl 2):381-3. doi: 10.1111/j.1365-2125.1976.tb03729.x.
9
New antipsychotic medications: strategies for evaluation and selected findings.新型抗精神病药物：评估策略与部分研究结果
Schizophr Res. 1997 Oct 30;27(2-3):249-59. doi: 10.1016/S0920-9964(97)00089-3.
10
Introduction: evaluating the evidence: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and beyond.引言：评估证据：临床抗精神病药物干预有效性试验（CATIE）及其他
J Clin Psychiatry. 2007;68 Suppl 1:3-4.
本文引用的文献
1
Sudden removal of tranquilizing drugs from chronic psychiatric patients.
J Nerv Ment Dis. 1960 Sep;131:252-5. doi: 10.1097/00005053-196009000-00007.
2
Riboflavine as an indicator of drug taking behaviour.
Med J Aust. 1967 Feb 4;1(5):202-4. doi: 10.5694/j.1326-5377.1967.tb21152.x.
3
Physiologic and clinical effects of chlorpromazine and their relationship to plasma level.氯丙嗪的生理和临床效应及其与血浆水平的关系。
Clin Pharmacol Ther. 1972 Nov-Dec;13(6):931-46. doi: 10.1002/cpt1972136931.
4
Clinical biostatistics. XIV. The purposes of prognostic stratification.临床生物统计学。十四、预后分层的目的。
Clin Pharmacol Ther. 1972 Mar-Apr;13(2):285-97. doi: 10.1002/cpt1972132285.
5
Integrating psychiatric research with clinical training: N=1.将精神病学研究与临床培训相结合：样本量N = 1。
J Nerv Ment Dis. 1972 Mar;154(3):206-12. doi: 10.1097/00005053-197203000-00010.
6
Trial of maintenance therapy in schizophrenia.精神分裂症维持治疗试验
Br Med J. 1971 Sep 11;3(5775):599-604. doi: 10.1136/bmj.3.5775.599.
7
Life events and psychiatric disorders. 2. Nature of causal link.生活事件与精神障碍。2. 因果联系的性质。
Psychol Med. 1973 May;3(2):159-76. doi: 10.1017/s0033291700048492.
8
Life-events and psychiatric disorders. 1. Some methodological issues.
Psychol Med. 1973 Feb;3(1):74-87. doi: 10.1017/s0033291700046365.
9
Influence of selection of patients on results of clinical trials.患者选择对临床试验结果的影响。
Br Med J. 1973 Oct 20;4(5885):156-8. doi: 10.1136/bmj.4.5885.156.
10
Role of fluphenazine decanoate in lessening the burden of chronic schizophrenics on the community.
Psychol Med. 1973 May;3(2):141-58. doi: 10.1017/s0033291700048480.
Zotero 插件